GSA Capital Partners LLP bought a new position in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,669,033 shares of the company’s stock, valued at approximately $1,973,000.
Several other hedge funds have also bought and sold shares of the business. Scientech Research LLC bought a new stake in Tenaya Therapeutics during the 3rd quarter valued at $27,000. Geode Capital Management LLC lifted its stake in shares of Tenaya Therapeutics by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 1,193,355 shares of the company’s stock valued at $849,000 after buying an additional 17,820 shares in the last quarter. Mirador Capital Partners LP grew its holdings in shares of Tenaya Therapeutics by 2.0% during the second quarter. Mirador Capital Partners LP now owns 905,097 shares of the company’s stock valued at $669,000 after buying an additional 18,180 shares during the last quarter. Integrity Wealth Solutions LLC acquired a new position in shares of Tenaya Therapeutics during the first quarter valued at about $27,000. Finally, Cetera Investment Advisers increased its position in shares of Tenaya Therapeutics by 107.0% during the fourth quarter. Cetera Investment Advisers now owns 106,425 shares of the company’s stock worth $76,000 after acquiring an additional 55,000 shares in the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.
Tenaya Therapeutics Stock Performance
NASDAQ TNYA opened at $0.73 on Monday. The business has a fifty day simple moving average of $0.76 and a 200 day simple moving average of $0.76. Tenaya Therapeutics, Inc. has a 12 month low of $0.53 and a 12 month high of $2.35. The firm has a market capitalization of $163.26 million, a P/E ratio of -1.37 and a beta of 2.83.
Analysts Set New Price Targets
A number of research firms recently weighed in on TNYA. Wall Street Zen lowered shares of Tenaya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings upgraded Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tenaya Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.
View Our Latest Report on Tenaya Therapeutics
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.
Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.
Featured Articles
- Five stocks we like better than Tenaya Therapeutics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Want to see what other hedge funds are holding TNYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Free Report).
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
